Pearl Prepares for Phase III Push with $65M Series D
Pearl Therapeutics Inc.'s consortium of investors returned for a Series D financing round worth $65 million. The funds, provided by lead investor Vatera Capital, along with 5AM Ventures, Clarus Ventures and New Leaf Venture Partners, will support Phase III studies of Pearl's candidate for chronic obstructive pulmonary disease (COPD), PT003.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter